Since inhibitors based on small molecules and macromolecules are not selective and potent enough, new compounds, including bicyclic peptides, have been developed in recent years.
Bicyclic peptides are new generation therapeutic molecules which exhibit properties typical of monoclonal antibodies (high affinity and specificity of the target) and of small molecules (high plasma stability and good tissue penetration).
Computational design implementation has led to the synthesis of peptide libraries with 2 to 17 times the potency of the most promising compound found so far. These patented bicyclic peptides can detect and inhibit the human urokinase enzyme uPA, a serine protease that stimulates cancer cell motility and is involved in the process of tumor metastasis. Bicyclic peptides generally have low toxicity and immunogenicity and can be formulated in pharmaceutical compositions for parenteral administration, also in combination with other active principles.

TRL (Technology Readiness Level)

TRL 3 / 9

Inventors

Alessandro
Angelini

Laura
Cendron

Nicola
Frasson

Ylenia
Mazzocato

Download the brochure

  • A treatment for fibrotic disease

    Fibrosing diseases are chronic pathologies, with a different genesis, characterized by various types of cellular or extracellular infiltrates determining a progressive destruction of the parenchyma, which is replaced by fibrous tissue, causing progressive damage to organ anatomy. Fibrosing diseases are[...]

  • siRNAEEC – Novel treatment to mitigate the Ectrodactyly-Ectodermal dysplasia- Clefting (EEC) associated blindness

    The Ectrodactyly-Ectodermal dysplasia-Clefting (EEC) syndrome is a rare genetic disorder due to mutations in the p63 gene and characterized by limb defects, orofacial clefting, ectodermal dysplasia, and ocular surface defects that lead to the loss of vision. Currently no specific[...]

  • New anti-tumoral approach: peptides targeting the hexokinase 2 protein

    Current antineoplastic treatments are not sufficient to cure cancer, in part due to lack efficacy and/or selectivity. Further, they often display significant side effects calling for new therapeutic approaches. The invention consists in the design, realization and administration of peptides[...]

Subscribe to newsletter

Follow the activities promoted by UniSMART Foundation